PROM1 and hepatocellular carcinoma: The results also showed high efficacy of the CD133 CAR T and PD-1 scFv cells through in vitro and in vivo experiments, suggesting that a strategy involving CD133 CAR T and PD-1 scFv cells could be a feasible therapeutic option for male patients with advanced HCC and elevated CD133 expression [113].